Clinical Trial Update: Bintrafusp Alfa in Previously Treated Patients With R/M Non-keratinizing NPC [Phase 2]

View source ↗

Summary

A Phase 2 study of bintrafusp alfa in previously treated patients with recurrent/metastatic nasopharyngeal carcinoma (non-keratinizing histology) has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nasopharyngeal Carcinoma

Drugs mentioned

• Bintrafusp alfa (bintrafusp alfa)

Snippet

Sponsor: The University of Hong Kong | Conditions: Nasopharyngeal Carcinoma, Recurrent Carcinoma | Phase 2 | Status: COMPLETED